{
  "links": "https://www.ycombinator.com/companies/invitris",
  "name": "Invitris",
  "headline": "Creating new protein-based drugs at scale",
  "batch": "W23",
  "description": "Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.\r\n\nOur killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.",
  "activity_status": "Active",
  "website": "https://invitris.com/",
  "founded_date": 2022.0,
  "team_size": 6.0,
  "location": "Munich, Germany",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; industry:nanotechnology; industry:drug-discovery",
  "founders": [
    {
      "name": "Patrick Grossmann, Founder",
      "description": "My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.",
      "linkedin": "https://www.linkedin.com/in/patrickgrossmannbioinformatics/"
    },
    {
      "name": "Kilian Vogele, Founder",
      "description": "Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.",
      "linkedin": "https://www.linkedin.com/in/kilian-vogele-21a321183/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown='[Skip to content](https://invitris.com/<#main>)\\n[![Invitris](https://invitris.com/wp-content/uploads/2022/06/21-1__2_-removebg-preview.png)](https://invitris.com/<https:/invitris.com/>)\\n  * [Home](https://invitris.com/<https:/invitris.com/>)\\n  * [About us](https://invitris.com/<https:/invitris.com/about-us/>)\\n  * [Technology](https://invitris.com/<https:/invitris.com/technology/>)\\n  * [Contact](https://invitris.com/<https:/invitris.com/contact/>)\\n  * [Careers](https://invitris.com/<https:/invitris.com/careers/>)\\n\\n\\n[![Invitris](https://invitris.com/wp-content/uploads/2022/06/21-1__2_-removebg-preview.png)](https://invitris.com/<https:/invitris.com/>)\\nToggle Menu\\n# Enabling the protein era\\n[ Technology ](https://invitris.com/<https:/invitris.com/technology/>)\\n## Replacing a 100 year old method\\n#### One Platform to conquer all. \\nWe **partner** with other companies to: **A) create new products** and **B) manufacture them**.\\nOur **universal platform technology** enables generating synthetic proteins at the highest yields and purity. This platform is based on cell-free expression and allows **creating entirely novel proteins** with entire novel mechanisms of action and **manufacture them** at scale. \\nWhile our primary focus is on **human therapeutics** , we have worked on **industrial** use-cases too. We currently employ **prokaryotic cell-free expression systems** and are advancing our technology to **eukaryotic cell-free expression systems**.\\n**Our specialities are:** phages, tailocins, endolysins, neoantigens, vaccines, antibodies, and toxic proteins (e.g., nucleases and proteases).\\n**Our industries are:** human health, agriculture, animal health, food, and industrial chemistry.\\n![](https://invitris.com/wp-content/uploads/2023/03/Slide7-768x369.jpg)\\n![](https://invitris.com/wp-content/uploads/2024/03/Black-768x285.png)\\n![](https://invitris.com/wp-content/uploads/2024/03/meta-768x401.png)\\n## Supported by\\n![](https://invitris.com/wp-content/uploads/2022/06/Prasentation2.png)\\n[ ![](https://invitris.com/wp-content/uploads/2022/06/21-1__2_-removebg-preview.png) ](https://invitris.com/<https:/invitris.com>)\\nUseful Links\\n  * [ About us ](https://invitris.com/<https:/invitris.com/about-us/>)\\n  * [ Contact ](https://invitris.com/<https:/invitris.com/contact/>)\\n  * [ Imprint ](https://invitris.com/<https:/invitris.com/imprint/>)\\n\\n\\n[Scroll to top ](https://invitris.com/<#wrapper>)Scroll to top\\n  * [Home](https://invitris.com/<https:/invitris.com/>)\\n  * [About us](https://invitris.com/<https:/invitris.com/about-us/>)\\n  * [Technology](https://invitris.com/<https:/invitris.com/technology/>)\\n  * [Contact](https://invitris.com/<https:/invitris.com/contact/>)\\n  * [Careers](https://invitris.com/<https:/invitris.com/careers/>)\\n\\n\\n' markdown_with_citations='Skip to content⟨1⟩\\n![Invitris⟨2⟩](https://invitris.com/<https:/invitris.com/>)\\n  * Home⟨3⟩\\n  * About us⟨4⟩\\n  * Technology⟨5⟩\\n  * Contact⟨6⟩\\n  * Careers⟨7⟩\\n\\n\\n![Invitris⟨2⟩](https://invitris.com/<https:/invitris.com/>)\\nToggle Menu\\n# Enabling the protein era\\n Technology ⟨5⟩\\n## Replacing a 100 year old method\\n#### One Platform to conquer all. \\nWe **partner** with other companies to: **A) create new products** and **B) manufacture them**.\\nOur **universal platform technology** enables generating synthetic proteins at the highest yields and purity. This platform is based on cell-free expression and allows **creating entirely novel proteins** with entire novel mechanisms of action and **manufacture them** at scale. \\nWhile our primary focus is on **human therapeutics** , we have worked on **industrial** use-cases too. We currently employ **prokaryotic cell-free expression systems** and are advancing our technology to **eukaryotic cell-free expression systems**.\\n**Our specialities are:** phages, tailocins, endolysins, neoantigens, vaccines, antibodies, and toxic proteins (e.g., nucleases and proteases).\\n**Our industries are:** human health, agriculture, animal health, food, and industrial chemistry.\\n![](https://invitris.com/wp-content/uploads/2023/03/Slide7-768x369.jpg)\\n![](https://invitris.com/wp-content/uploads/2024/03/Black-768x285.png)\\n![](https://invitris.com/wp-content/uploads/2024/03/meta-768x401.png)\\n## Supported by\\n![](https://invitris.com/wp-content/uploads/2022/06/Prasentation2.png)\\n ![⟨2⟩ ](https://invitris.com/<https:/invitris.com>)\\nUseful Links\\n  *  About us ⟨4⟩\\n  *  Contact ⟨6⟩\\n  *  Imprint ⟨8⟩\\n\\n\\nScroll to top ⟨9⟩Scroll to top\\n  * Home⟨3⟩\\n  * About us⟨4⟩\\n  * Technology⟨5⟩\\n  * Contact⟨6⟩\\n  * Careers⟨7⟩\\n\\n\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://invitris.com/<#main>: Skip to content\\n⟨2⟩ https://invitris.com/wp-content/uploads/2022/06/21-1__2_-removebg-preview.png: ![Invitris\\n⟨3⟩ https://invitris.com/<https:/invitris.com/>: Home\\n⟨4⟩ https://invitris.com/<https:/invitris.com/about-us/>: About us\\n⟨5⟩ https://invitris.com/<https:/invitris.com/technology/>: Technology\\n⟨6⟩ https://invitris.com/<https:/invitris.com/contact/>: Contact\\n⟨7⟩ https://invitris.com/<https:/invitris.com/careers/>: Careers\\n⟨8⟩ https://invitris.com/<https:/invitris.com/imprint/>:  Imprint \\n⟨9⟩ https://invitris.com/<#wrapper>: Scroll to top \\n' fit_markdown='' fit_html=''",
  "generated_description": "### Summary of Invitris\n\n**Company Overview:**  \nInvitris, founded in 2022 and located in Munich, Germany, is disrupting the biopharmaceutical landscape with its innovative technology platform that simplifies the creation of novel biological drugs. Their mission? To create new protein-based drugs efficiently and at scale.\n\n**Technology and Efficiency:**  \nAt the heart of Invitris' approach is a patent-pending technology that transforms DNA into synthetic proteins. This process makes drug creation over 10,000 times more efficient while reducing material costs by nearly 100 times. Recently, their cutting-edge technology captured attention in *Science* magazine, highlighting the significance of their advancements in the field.\n\n**Key Application:**  \nThe company is particularly focused on combatting antibiotic-resistant infections through the development of synthetic bacteriophages — a response to a looming health crisis that threatens to outpace cancer mortality rates. \n\n**Team and Support:**  \nInvitris is a compact yet ambitious team of six and is part of the Y Combinator Batch W23, leveraging top-tier guidance and support in the startup scene. Their growth and partnerships are pivotal in helping them create new products and manufacture them effectively.\n\n**Specializations and Industries:**  \nWhile the primary focus is on human health, Invitris' technology has applications across several sectors, including agriculture and industrial chemistry. They specialize in a variety of products such as phages, vaccines, antibodies, and more, employing both prokaryotic and eukaryotic cell-free expression systems.\n\n**Why It Matters:**  \nIn a world facing urgent health challenges from antibiotic resistance, Invitris is positioned not just as a biotech company but as a vital player in the future of drug discovery and development. They support a broad range of industries and are paving the way for a new era in protein-based therapeutics.\n\n**Learn More:**  \nCurious to delve deeper? Check out their [website](https://invitris.com/) for more information on their technology and applications.\n\n### Key Constants:\n- **Founded:** 2022\n- **Location:** Munich, Germany\n- **Team Size:** 6\n- **Industry Tags:** Biotech, Nanotechnology, Drug-discovery\n- **Key Partner:** Nan\n\nInvitris represents the kind of bold innovation that can change paradigms, making it an exciting company to watch in the evolving biotech landscape."
}